Novartis’ Beovu (brolucizumab) Receives NICE Recommendation for Diabetic Macular Oedema
- The NICE has issued FAD recommending Beovu as a treatment option for use on the NHS for visual impairment due to DMO. Beovu’s recommended dosage of 6mg was administered by inj. q6w for the first 5 doses
- The recommendation was based on the P-III (KESTREL) & (KITE) trials for brolucizumab vs aflibercept. The results showed an improvement in visual impairment & has the potential for fluid resolution & minimize treatment burden, patients with brolucizumab & aflibercept were treated on 12wk. & 8wk. intervals in the 1st yr., following the loading phase, disease activity moved to q8w
- Additionally, ~50% of patients (55.1% in KESTREL & 50.3% in KITE) remained on a 12wk. dosing interval @1yr.
Ref: Novartis | Image: Novartis
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.